Professor Robert Moots

Robert Moots is Professor of Rheumatology at the University of Liverpool and honorary Consultant Rheumatologist at Aintree University Hospital. Qualifying in Medicine (with distinction) in London, he earned his PhD in immunology at the University of Oxford and subsequently moved to Harvard Medical School to continue his work, before returning to the UK to establish a new academic rheumatology group at Liverpool.

Professor Moots’ practice integrates cutting edge clinical care with research. Provision of clinical service remains an important part of his work: as well as caring for more prevalent rheumatic conditions, he particularly specialises in inflammatory conditions such as rheumatoid arthritis and vasculitis. Amongst other achievements, he is Director of the new UK National Centre for Behçet’s disease, at Aintree.

Prof Moots’ research focuses on clinical and laboratory aspects of inflammatory rheumatic diseases, from bench to bedside and a major interest in neutrophils in inflammation.  He has published extensively (more than 150 papers in major journals), his group holds around £3million in competitive research funding, he is active in international societies and committees and each year he receives invitations to lecture around the world. Prof Moots advises the pharmaceutical industry globally, the UK National Institute for Health Care Excellence NICE (devising UK national quality standards for RA), is medical advisor to UK patient groups and has recently ended a successful term as Editor-in-Chief of Rheumatology. 
 

Clinical Interests

Arthritis (including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, spondylarthritis, fibromyalgia); inflammatory connective tissue diseases (Including lupus/SLE, systemic sclerosis/scleroderma, Sjögren’s syndrome, mixed connective tissue disease); systemic vasculitis (Including Behçet’s syndrome, ANCA positive vasculitis, granulomatosis with polyangiitis); refractory rheumatological conditions, diagnostic difficulties, immunotherapy, clinical trials.